ReviewInfectious diseases and therapy2016
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease.
Review in Infectious diseases and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04415229 (Seasonality of Respiratory Syncytial Virus), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Seasonality of Respiratory Syncytial Virus (RSV) Bronchiolitis in Children Aged 2 Years or Less Hospitalized in Martinique (French West Indies) a Tropical Area From 2007 to 2018
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk Factors for Severe Bronchiolitis in Australian and Aotearoa New Zealand Infants: A Systematic Review.Journal of paediatrics and child health · 2025Pooled it
- Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies.Epidemiology and infection · 2020Pooled it
- RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.Vaccines · 2026Review
- Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.Cost effectiveness and resource allocation : C/E · 2026Article
- The incidence and risk factors of bronchopulmonary dysplasia in extremely preterm infants included in the Polish National Program for Respiratory Syncytial Virus Prophylaxis.Archives of medical science : AMS · 2026Article
- Characteristics and outcomes of infants with bronchopulmonary dysplasia discharged on home oxygen at Charlotte Maxeke Johannesburg Academic Hospital, South Africa.African journal of thoracic and critical care medicine · 2026Article
- Article
- Genetic characterization of the respiratory tract viruses in Jilin, Northeast China, 2023.Frontiers in public health · 2025Article
- A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan.Frontiers in pediatrics · 2025Article
- An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.Italian journal of pediatrics · 2024Article
- Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.Lancet regional health. Americas · 2023Article
- Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases.Seminars in perinatology · 2023Review
- Association between prenatal and neonatal risk factors and development of bronchiolitis in early life.Asia Pacific allergy · 2023Article
- Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions.Frontiers in pharmacology · 2023Review
- Murine Neonatal Oxidant Lung Injury: NRF2-Dependent Predisposition to Adulthood Respiratory Viral Infection and Protection by Maternal Antioxidant.Antioxidants (Basel, Switzerland) · 2021Article
- Burden of illness in infants and young children hospitalized for respiratory syncytial virus: A rapid review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
- The Burden of Respiratory Syncytial Virus in Children Under 2 Years of Age in a Rural Community in Maharashtra, India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Prevalence and Risk Factors of Respiratory Syncytial Virus in Children under 5 Years of Age in the WHO European Region: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2021Article
- Current State of Respiratory Syncytial Virus Disease and Management.Infectious diseases and therapy · 2021Review
- Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.Influenza and other respiratory viruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe REGAL (RSV evidence-a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD).
methodsA systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among infants with CLD/BPD who were not prophylaxed, as well as studies reporting RSV-associated morbidity, mortality, and healthcare costs, were included. Burdens of disease data were compared with preterm infants without CLD/BPD, other high-risk groups and term infants. Study quality and strength of evidence (SOE) were graded using recognized criteria.
resultsA total of 1837 studies were identified and 39 were included. CLD/BPD is a significant independent risk factor for RSV hospitalization [RSVH (odds ratio 2.2-7.2); high SOE]. Infants and young children with CLD/BPD had high RSVH rates which were generally similar in Europe, the United States, and Canada, mostly varying between 12 and 21%. Infants with CLD also had a longer length of hospital stay than other high-risk groups and term infants (high SOE). On average, infants spent 4-11 days in hospital (moderate SOE). Once hospitalized for RSV, affected children were at risk for a more severe course of disease than children with no RSVH (moderate SOE).
conclusionSevere RSV infection in infants and young children with CLD/BPD poses a significant health burden in Western countries. Further studies focussing on the burden of RSV infection in this well-recognized population at high risk for severe disease are needed to help improve outcomes and plan allocation of healthcare resources.
fundingAbbVie.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.